Please login to the form below
REGN5458
This page shows the latest REGN5458 news and features for those working in and with pharma, biotech and healthcare.
GSK files anti-BCMA drug for myeloma after second trial win
Other drugs making their way through development include bispecific antibodies from Amgen ( AMG 420), Regeneron (REGN5458) and Bluebird Bio/Bristol-Myers Squibb (CC-92369), as well as ADCs from AstraZeneca (MEDI2228)
Latest news
-
Regeneron reveals first data for bispecific antibody in multiple myeloma
Regeneron has made its first appearance on the BCMA scene, revealing data for its bispecific antibody candidate REGN5458 in multiple myeloma. . ... The much anticipated first results from the first two dose groups in the phase 1/2 trial of REGN5458 were
-
Sanofi and Regeneron re-jig immuno-oncology deal
The two candidates selected as most promising are REGN5458 (aka BCMAxCD3), a BCMA and CD3 targeting bispecific antibody and REGN4018, a MUC16 and CD3 targeting bispecific antibody.
Regeneron reveals first data for bispecific antibody in multiple myeloma
Sanofi and Regeneron re-jig immuno-oncology deal
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
